Heidelberg

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of In … Pending
  2025-523087-20-00 5 Duchenne muscular dystrophy
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 5 Relapsed/refractory primary central nervous system lymphoma
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Pending
  2025-523495-23-00 5 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally … Pending
  2025-523524-53-00 9 ADVANCED OR METASTATIC RENAL CELL CARCINOMA
• A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic sy … Pending
  2025-523597-17-00 4 Painful diabetic peripheral neuropathy
• Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). Pending
  2025-523672-23-00 4 Metastatic Castrate Sensitive Prostate Cancer - mCSPC
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• Double-T - Improving outcomes in high-risk 2nd line relapsed/refractory Large B-Cell Lymphoma patients eligible for CAR-T-cell therapy with … Pending
  2025-523806-34-00 4 relapsed/refractory Large B-Cell Lymphoma
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Pending
  2025-523947-36-00 4 Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap
• The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID? Pending
  2025-524443-12-00 4 Post Covid Syndrome (PCS)
• A multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority trial to investigate shortening treatment duration in … Pending
  2026-525640-14-00 6 Candidemia
• Beamion 44: A study to test how well zongertinib is tolerated by people with advanced non-small cell lung cancer with HER2 mutations when gi … Recruiting
  2025-523567-38-00 4 2026-06-02 locally advanced or metastatic NSCLC
• PREFer Recruiting
  2024-520138-31-00 4 2026-06-01 Early-stage favorable classic Hodgkin lymphoma
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A clinical trial of ifinatamab deruxtecan in people with advanced esophageal cancer (MK-3475-06F) Recruiting
  2026-525213-31-00 4 2026-05-21 Esophageal squamous cell carcinoma
• AURA-IPF: A Randomized Phase 2 Study to evaluate the safety and efficacy of AP02 (nintedanib solution) in IPF Recruiting
  2025-523431-19-00 4 2026-05-20 Idiopathic Pulmonary Fibrosis (IPF)
• Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting
  2025-522107-18-00 4 2026-05-19 Locally advanced or metastatic Non-Small Cell Lung Cancer
• A clinical study of tulisokibart in people with psoriatic arthritis (MK-7240-015) Recruiting
  2025-520997-21-00 4 2026-05-08 Psoriatic arthritis​​
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• L19IL2/TNF in patients with basal cell carcinoma Recruiting
  2025-523230-77-00 4 2026-04-27 Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
• L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting
  2025-523231-19-00 4 2026-04-27 Cutaneous Squamous Cell Carcinoma
• RENEW - A Phase 2 Study of the Safety, Tolerability and Efficacy of LTI-03 in Patients with Idiopathic Pulmonary Fibrosis Recruiting
  2025-520715-13-00 4 2026-04-22 Idiopathic Pulmonary Fibrosis

Showing 25–48 of 732 trials